Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LA5K | ISIN: SE0000872095 | Ticker-Symbol: B6E
Tradegate
06.06.25 | 15:08
28,160 Euro
+0,36 % +0,100
1-Jahres-Chart
SWEDISH ORPHAN BIOVITRUM AB Chart 1 Jahr
5-Tage-Chart
SWEDISH ORPHAN BIOVITRUM AB 5-Tage-Chart
RealtimeGeldBriefZeit
27,96028,32016:40
28,08028,34016:29

Aktuelle News zur SWEDISH ORPHAN BIOVITRUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15:42Swedish Orphan Biovitrum AB: Sobi and Apellis: Aspaveli/Empaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases151STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating...
► Artikel lesen
15:18Apellis Pharmaceuticals, Inc.; Sobi: Apellis and Sobi Announce EMPAVELI (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN8
SWEDISH ORPHAN BIOVITRUM Aktie jetzt für 0€ handeln
MiSwedish Orphan Biovitrum AB: Sobi Showcases Breadth of data in C3G/primary IC-MPGN at ERA 2025224STOCKHOLM, June 4, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will have a strong scientific presence at this year's ERA congress in Vienna (4-7 June) with a total of eight presentations: six...
► Artikel lesen
DiSwedish Orphan Biovitrum AB: Invitation: Sobi's Aspaveli - 52-week Phase 3 VALIANT data in nephrology185VALIANT Phase 3 data in nephrology after presentation at the ERA congress. STOCKHOLM, June 3, 2025 /PRNewswire/ -- Investors, analysts, and members of the media are invited to a conference...
► Artikel lesen
28.05.Swedish Orphan Biovitrum AB: Sobi to share new clinical data and research at EULAR 2025341STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from...
► Artikel lesen
08.05.Swedish Orphan Biovitrum AB: Bulletin from Sobi's Annual General Meeting (AGM)925STOCKHOLM, May 8, 2025 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) AGM was convened today on 8 May 2025. At the AGM, the shareholders, in accordance with the proposed resolutions...
► Artikel lesen
30.04.Kepler Cheuvreux lifts SOBI stock rating, cuts price target to SEK35015
29.04.Swedish Orphan Biovitrum AB reports Q1 results1
29.04.Swedish Orphan Biovitrum AB Bottom Line Advances In Q1-
29.04.Swedish Orphan Biovitrum AB: Sobi publishes Q1 2025 report: Portfolio continues to deliver282STOCKHOLM, April 29, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2025 First Quarter 2025 Total revenue increased...
► Artikel lesen
25.04.Swedish Orphan Biovitrum AB: Sobi and Sanofi's Foundation S extend partnership with the World Federation of Hemophilia Humanitarian Aid Program536Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistanceSTOCKHOLM, April 25, 2025 /PRNewswire/ -- Sobi® (STO: SOBI)...
► Artikel lesen
25.04.Sanofi and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program511Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistanceMONTREAL, April 25, 2025 /PRNewswire/ -- The World Federation...
► Artikel lesen
23.04.Swedish Orphan Biovitrum AB: Sobi presents clinical data at WFH 2025 Comprehensive Care Summit328STOCKHOLM, April 23, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) presents clinical data aimed at updating the global haemophilia community attending this year's WFH 2025 Comprehensive Care Summit...
► Artikel lesen
16.04.Berenberg cuts SOBI stock target to SEK360, maintains buy3
15.04.Swedish Orphan Biovitrum AB: Invitation: Sobi's Q1 report577STOCKHOLM, April 15, 2025 /PRNewswire/ -- Sobi plans to publish its report for the first quarter of 2025 on 29 April 2025 at 08:00 CET. Investors, analysts, and the media are invited...
► Artikel lesen
01.04.Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)290STOCKHOLM, April 1, 2025 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting")...
► Artikel lesen
31.03.Swedish Orphan Biovitrum AB: Sobi publishes Annual and sustainability report for 2024233STOCKHOLM, March 31, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in...
► Artikel lesen
27.03.Ionis and Sobi agree on olezarsen commercialisation3
27.03.IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi1
26.03.Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.8
Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1